Ankit Sabharwal, Mark D Wishman ... Stephen C Ekker
A revertible Leigh Syndrome French Canadian Type (LSFC) disease model recapitulates the clinical phenotypes which can be rescued using a liver-specific genetic model therapy.
Meredith A Sommars, Krithika Ramachandran ... Grant D Barish
B cell lymphoma 6 (BCL6) represses fasting gene expression by opposing peroxisome proliferator-activated receptor alpha (PPARa) activity at enhancers, and its ablation protects against steatosis by enhancing fatty acid catabolism.
Pharmacological activation of farnesoid X (FXR) receptor by hammerhead-type agonists induces a novel enhancer RNA, termed Fincor, contributing to the amelioration of nonalcoholic steatohepatitis in mice.
Melanocortin 1 receptor (MC1-R) deficiency in hepatocytes increases cholesterol levels in the circulation and liver in mice, while selective activation of MC1-R reduces cellular cholesterol content in cultured hepatocytes.
Antibody-mediated neutralisation of Gremlin-1 was ineffective in treating fibrosis in metabolic dysfunction-associated steatohepatitits, likely due to low hepatic expression in a subset of myofibroblasts and redundant Gremlin-1 signalling.
Lutheran is a novel marker for classification of bile duct remodeling in distinct liver injury, and an interesting functional molecule for investigating the nature of liver stem/progenitor cells during regeneration.
Identifying xanthohumol and its derivatives as PPARγ anatagonists provides new insight into how natural compounds beneficially treat obesity and metabolic syndrome, and provide new compounds for therapeutic development.
Venkateshwari Varadharajan, Iyappan Ramachandiran ... J Mark Brown
MBOAT7 loss of function in hepatocytes contributes to ethanol-induced liver injury, offering crucial insights into the dysregulated lipid metabolism and impaired autophagy associated with advanced liver disease.
